INFLUENCE OF COMBINATION ANTIHYPERTENSION THERAPY ON THE PARAMETERS OF VESSEL WALL RIGIDITY IN NON-CONTROLLED ARTERIAL HYPERTENSION PATIENTS WITH DEPRESSION

Aim. Assessment of combination of antihypertension therapy (CAT) including antidepressant, on the main parameters of ambulatory blood pressure monitoring (ABPM), vascular wall rigidity parameters and central aortic pressure in patients with non-controlled arterial hypertension (NCAH) and depression disorders (DD).

Material and methods. Totally, 160 patients studied with NCAH and DD, whom CAT was prescribed, that included angiotensine converting enzyme inhibitor perindopril 10 mg/day and diuretic indapamide SR 1,5 mg/day. Patients were randomized to 2 groups: in 1 group, to the therapy antidepressant escitalopram (Es) was added 10 mg per day; in 2 group — calcium antagonist amlodipine 5-10 mg per day. At baseline and in 24 weeks all included patients underwent general clinical assessment, ABPM (hardware ABPM by LLC “Piotr Telegin” BPLab Vasotens, Russia) under circumstances of free exertion regimen, with measurements interval 25 min day and 50 minutes nighttime. The following was assessed: mean daily, daytime and nighttime systolic pressure (sBP), diastolic pressure (dBP), BP variability, time index of AH, level and speed of morning BP increase, circadian index, pulse BP. In addition, the mean daily parameters of vessel rigidity were evaluated: time of reflected wave spread, evaluative velocity of pulse wave in aorta, augmentation index (Alx, %); main central aortic pressure parameters were checked: sBP (sBPao, mmHg), dBP (dBPao, mmHg), mean pressure in aorta (BPaom, mmHg), augmentation index in aorta (Alxao, %). Questionnaires were completed by patients: anxiety and depression HADS, selfestimation of depression by Tsung, Spielberger anxiety, Vein vegetative changes, life quality questionnaire SF-36 and ABPM.

Results. In 24 weeks of therapy the positive statistically significant dynamics of depression spectrum disorders was marked in Es group, but in the 2nd group, by the majority of parameters depression level remained high. Usage of antidepressant as a part of CAT led to significant decrease of anxiety and vegetative changes, but in “traditional” therapy group there was increase of anxiety and vegetative disorders remained. In 1st group of patients taking antidepressant there was more prominent and statistically significant comparing to control group improvement of life quality parameters by SF-36. CAT with Es led to decrease of BP to target levels in a half of patients in 4 weeks, but in controls, to reach target values, in 75,6% it was need to increase amlodipine dosage up to 10 mg daily. Comparison of dynamics of ABPM parameters in 24 weeks showed that in the 1st group there was significantly more prominent improvement of main ABPM parameters comparing to controls.

Conclusion. Usage of Es in CAT led to significant improvement of psychoemotional and vegetative status of patients, decrease of the main symptoms of depression and anxiety, improvement of life quality parameters, more rapid target BP achievement and more significant improvement of main ABPM parameters, than therapy without antidepressant.

1. Chazova IE, Fomin VV, Razuvaeva MA, et al. Resistance and uncontrolled hypertension in the Russian Federation: epidemiological characteristics and treatment approaches (Russian Register of uncontrolled and refractory hypertension REGATA). Kardiologicheskij Vestnik. 2011; 6 (1): 40-8. Russian (Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Резистентная и неконтролируемая артериальная гипертония в Российской Федерации: эпидемиологическая характеристика и подходы к лечению (Российский регистр неконтролируемой и резистентной артериальной гипертонии РЕГАТА «РЕзистентная Гипертония АрТериАльная»). Кардиологический вестник. 2011; 6 (1): 40-8.

2. Boytsov SA, Balanova JuA, Shal'nova SA, et al. Hypertension among 25-64: prevalence, awareness, treatment and control. According to studies ESSE. Cardiovascular therapy and prevention. 2014; 4: 4-14. Russian (Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 4: 4-14).

3. Chazov EI, Oganov RG, Pogosova GV, et al. Clinical and epidemiological study of depression program in cardiology practice in patients with hypertension and coronary heart disease (KOORDINATA): results of a multicenter study. Cardiology. 2007; 3: 28-37. Russian (Чазов Е.И., Оганов Р.Г., Погосова Г.В. и др. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): результат многоцентрового исследования. Кардиология. 2007; 3: 28–37).

4. Moise N, Davidson KW, Chaplin W, et al. Depression and clinical inertia in patients with uncontrolled hypertension. JAMA Intern Med. 2014; 115.

5. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension, 2007; 50: 197-203.

6. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25.

7. Paranthaman R, Greenstein AS, Burns AS, et al. Vascular function in older adults with depressive disorder. Biol Psychiatry. 2010;15; 68(2): 133-9.

8. Seldenrijk A, van Hout HP, van Marwijk HW, et al. Depression, anxiety, and arterial stiffness. Biol Psychiatry. 2011; 15; 69 (8): 795-803.

9. The Federal guidelines for the diagnosis and treatment of recurrent depressive disorder. http://psychiatr.ru/ (2013). Russian (Федеральные клинические рекомендации по диагностике и лечению рекуррентного депрессивного расстройства. http://psychiatr.ru/ (2013)).

10. Vasjuk JuA, Dovzhenko TV, Shkol'nik EL. Features pathogenetic relationships of the depression and cardiovascular diseases. Mental disorders in general medicine. 2007; 2 (1): 8-12. Russian (Васюк Ю.А., Довженко Т.В., Школьник Е.Л. Особенности патогенетической взаимосвязи депрессии и сердечно-сосудистых заболеваний. Психические расстройства в общей медицине. 2007; 2(1): 8-12).

11. Serretti A, Olgiati P. Biochemistry of depressive disorders. Role of serotonin, amino acid neurotransmitters, substance P and neurosteroids. Clinical Neuropsychiatry. 2008; 5(5): 225-41.

12. Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary heart disease. Psychosom. Med. 2005; 67 (1): 29-33.

13. Bogner HR, de Vries HF. Integration of depression and hypertension treatment: a pilot, randomized controlled trial. Ann Fam Med. 2008; 6: 295-301.

14. Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence. 2012; 6: 853.

15. Kukes VG, Ostroumova OD, Starodubcev AK. Calcium channel blockers: modern aspects of usage in cardiology. Consilium medicum 2006; 8 (11): 113-7. Russian. (Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum 2006; 8 (11): 113-7).

16. Thomas van Sloten, Mitchell GF, Sigurdsson S. et al. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. J Psychiatry Neuroscience. 2015; 41(1): 140334.

17. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: The potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003; 8: 365-70.

18. Herken H, Gurel A, Selek S. et al. Adenosine deaminase, nitric oxide, superoxide dismutase and xanthine oxidase in patients with major depression: Impact of antidepressant treatment. Arch. Med. Res. 2007; 38: 247-52.

19. Lekakis J, Ikonomidis I, Papoutsi Z, et al. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int. J. Cardiol. 2010; 139: 150-8.